dupilumab
R668-AD-1924
Phase 3 small_molecule completed
Quick answer
dupilumab for Moderate to Severe Atopic Hand and Foot Dermatitis is a Phase 3 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Moderate to Severe Atopic Hand and Foot Dermatitis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed